- Led by RTW Investments with Syndicate Investors Venrock and Tavistock; Full Existing Investor Participation - MONTREAL and CHARLOTTE, N. Car., October 25, 2018-- Milestone Pharmaceuticals, a late-stage biopharmaceutical company developing interventions for tachycardias, today announced the completion of an $80 million private financing. The equity financing included the support of new and existing institutional investors. Among new investors were RTW Investments, LP, who led the round, Venrock Healthcare Capital Partners, and Boxer Capital of Tavistock Group.